Gastrointestinal Cancer | Specialty

The OncLive Gastrointestinal Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of gastrointestinal (GI) cancers, including hepatocellular carcinoma, gastric cancer, pancreatic cancer, colorectal cancer, cholangiocarcinoma, esophageal cancer, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in GI cancers.

Targeted Therapies in Neuroendocrine Tumors

March 14th 2013

Emerging Treatment Options in Neuroendocrine Tumors

March 14th 2013

Role of Somatostatin Analogs in Neuroendocrine Tumors

March 14th 2013

Surgical Treatment of Neuroendocrine Tumors

March 14th 2013

The Genetics Behind Familial Neuroendocrine Tumors

March 14th 2013

Techniques for Diagnosing Neuroendocrine Tumors

March 14th 2013

Challenges in the Diagnosis of Neuroendocrine Tumors

March 14th 2013

The Role of Biomarkers in Neuroendocrine Tumors

March 14th 2013

Histological Classification of Neuroendocrine Tumors

March 14th 2013

Neuroendocrine Tumors: Introduction and Overview

March 14th 2013

Dr. Ford on Docetaxel in Esophagogastric Cancer

March 12th 2013

Hugo Ford, MD, from the Addenbrooke's Hospital in Cambridge, UK, describes which patients with metastatic esophagogastric cancer derive the greatest benefit from second-line treatment with docetaxel.

Dr. Abou-Alfa on Doxorubicin Plus Sorafenib in Liver Cancer

March 11th 2013

Ghassan K. Abou-Alfa, MD, Gastrointestinal Oncology Service, Memorial Sloan-Kettering Cancer Center, describes a study looking at sorafenib plus doxorubicin compared with doxorubicin alone in patients with advanced hepatocellular carcinoma.

Side Effects With Regorafenib Occur Early and Tend to Taper

March 8th 2013

The incidence of adverse effects with regorafenib in metastatic colorectal cancer is highest during the first treatment cycle and then diminishes over time.

Dr. Grady on Gene Profiling of CTCs in Pancreatic Cancer

March 7th 2013

William M. Grady, MD, from the Fred Hutchinson Cancer Research Center, discusses results from an ongoing prospective study looking at gene expression profiling of circulating tumor cells in patients with unresectable pancreatic cancer.

Similar Benefit, Lower Toxicity Found With Capecitabine- Versus Gemcitabine-based Chemoradiation in Pancreatic Cancer

March 6th 2013

Capecitabine produces similar local disease control with lower toxicity versus gemcitabine when combined with radiotherapy following induction chemotherapy in patients with locally advanced pancreatic cancer.

Bevacizumab Plus FOLFOXIRI May Offer New First-Line Option in mCRC

March 5th 2013

FOLFOXIRI plus bevacizumab improved progression-free survival and response rates with a modest increase in side effects compared with FOLFIRI plus bevacizumab in patients with unresectable metastatic colorectal cancer.

Dr. Bendell on Hsp90 Inhibition in Advanced Solid Tumors

March 4th 2013

Johanna Bendell, MD, Director of GI Cancer Research Program, Associate Director, Drug Development Program, Sarah Cannon Research Institute, discusses the inhibition of heat shock protein 90 (Hsp90) in advanced solid tumors.

Dr. Yao on Octreotide in Elderly Patients with NET

February 27th 2013

James C. Yao, MD, Associate Professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the analysis of the linked SEER-Medicare database in patients with neuroendocrine tumors.

Regorafenib Approved to Treat GIST

February 25th 2013

The FDA approved regorafenib for the treatment of gastrointestinal stromal tumors that cannot be removed surgically and no longer respond to other FDA-approved treatments for the disease.

Dr. Grothey on Bevacizumab Beyond Progression in mCRC

February 22nd 2013

Axel Grothey, MD, from the Mayo Clinic in Rochester, Minnesota, discusses the effectiveness of bevacizumab beyond disease progression in metastatic colorectal cancer.